| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 11(1); 2013 > Article
The Korean Journal of Urological Oncology 2013;11(1): 6-10.
전이 거세저항성 전립선암의 예후인자
김재헌, 양원재
순천향대학교 의과대학 비뇨기과학교실
Risk Factors for Metastatic Castrate-Resistant Prostate Cancer
Jae Heon Kim , Won Jae Yang
Department of Urology, Soonchunhyang University College of Medicine, Seoul, Korea
Published online: April 30, 2013.
Prostate cancer remains the most common type of cancer in men and the development of castrate-resistant disease seems inevitable. Metastatic castrate-resistant prostate cancer(mCRPC) is known to have a poor prognosis although some new chemotherapy, immunotherapy, and target therapy showed improvement in overall survival, which together drive a new treatment strategy for better prognosis. For risk factors of mCRPC, it could be divided by the period of 2004, in which Docetaxel treatment was established as standard method for mCRPC. The aim of this study is to describe risk factors for the prognosis of mCRPC. (Korean J Urol Oncol 2013;11:6-10)
Key Words: Castrate-resistant prostate cancer; Prognosis; Chemotherapy; Immunotherapy
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society. All rights reserved.                 Developed in M2PI
Close layer
prev next